<DOC>
	<DOCNO>NCT02949947</DOCNO>
	<brief_summary>The goal clinical research study compare InjectaferÂ® ( ferric carboxymaltose ) iron supplement learn may effective improve red blood cell count patient iron-deficiency anemia ( low red blood cell count ) gastrointestinal stromal tumor ( GIST ) and/or systemic therapy . The safety ferric carboxymaltose also study .</brief_summary>
	<brief_title>Efficacy Ferric Carboxymaltose Patients With Gastrointestinal Stromal Tumor ( GIST ) Receiving Systemic Therapy</brief_title>
	<detailed_description>Study Groups Study Drug Administration : If participant find eligible take part study , randomly assign ( flip coin ) 1 2 study group . This do one know one group well , , bad . - If participant Group A , receive ferric carboxymaltose injection vein 15 minute . Participant receive 2 injection 7 day apart ( example , Days 0 [ day participant assign study group ] 7 ) . - If participant Group B , take iron supplement mouth every day . This consider standard care iron deficiency anemia study staff discus participant iron supplement take risk . Participant study staff know group assign . Length Study : Participant may receive 2 injection ferric carboxymaltose ( participant Group A ) 3 month oral iron supplement ( participant Group B ) . Participant longer able take study drug intolerable side effect occur unable follow study direction . Participation study participant complete Week 24 visit . Study Visits : Baseline ( within 1 week participant assign study group ) : - Participant physical exam . - Participant complete questionnaire health . It take 5 minute complete . - Blood ( 1 tablespoon ) drawn routine test test level iron participant 's blood . One ( 1 ) time every week Months 1-3 , blood ( 1 tablespoon ) drawn routine test . During Weeks 4 , 8 , 12 , 24 : - Participant physical exam . - Participant complete questionnaire baseline . - Blood ( 1 tablespoon ) drawn routine test test level iron participant 's blood . During Weeks 16 20 , blood ( le 1 tablespoon ) draw test level iron participant 's blood . This investigational study . Ferric carboxymaltose FDA approve commercially available treat iron deficiency anemia ; however , consider investigational use patient cancer-related systemic therapy-related anemia . Up 50 participant take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Autonomic Nervous System Diseases</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>1 . GIST patient IDA plan start receive systemic therapy TKIs . 2 . Evidence iron deficiency anemia include , Hgb &lt; 11 g/dL , &gt; 8 g/dL ; transferrin saturation ( TSAT ) &lt; 20 % . 3 . No H/O allergic reaction iron therapy . 4 . No clinical sign active bleeding . 5 . Adequate hematologic ( ANC &gt; 1500/mm^3 , platelet count &gt; 100,000/mm^3 ) , renal ( serum creatinine &lt; 1.5mg/dL ) , hepatic ( serum bilirubin count &lt; 1.5 x normal serum glutamicoxaloacetic transaminase ( SGOT ) serum glutamic pyruvic transaminase ( SGPT ) &lt; 3 x normal ) function . 6 . Patients must Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 . 7 . Signed informed consent study . 8 . Male Females child bear potential must use acceptable method birth control include oral contraceptive , spermicide either condom , diaphragm cervical cap , use intrauterine device ( IUD ) abstinence . 9 . Patients require read understand English comply protocol requirement . 10 . Age &gt; =18 year old . 11 . Life expectancy least 6 month . 1 . Pregnant lactating woman . 2 . Patients comorbid condition render patient high risk treatment complication . 3 . Patient uncontrolled angina , congestive heart failure ( New York Heart Association &gt; class II know ejection fraction &lt; 40 % ) , uncontrolled cardiac arrhythmia hypertension , acute myocardial infarction within 3 month . 4 . Patient active seizure disorder . ( Patients previous history seizure disorder eligible study , evidence seizure activity , free antiseizure medication previous 5 year ) . 5 . Psychological , social , familial , geographical reason would prevent schedule visit followup . 6 . Prior surgery radiotherapy ( RT ) within 2 week study entry . 7 . Known hypersensitivity reaction component ferric carboxymaltose . 8 . Any anemia treatment within 4 week inclusion ( oral iron , IV iron , erythropoiesisstimulating agent ) , transfusion PRBCs 2 week . 9 . Hemochromatosis iron storage disorder . 10 . Known positive hepatitis evidence active disease . 11 . Patients overt bleed . 12 . Ferritin &gt; /= 800 ng/mL .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Malignant Neoplasms Mesothelial Soft Tissue</keyword>
	<keyword>Gastrointestinal Stromal Tumor</keyword>
	<keyword>GIST</keyword>
	<keyword>Iron-deficiency anemia</keyword>
	<keyword>Ferric Carboxymaltose</keyword>
	<keyword>Injectafer</keyword>
	<keyword>Iron supplement</keyword>
	<keyword>Health Questionnaire</keyword>
	<keyword>Survey</keyword>
</DOC>